Evidence map›Paper›PMID 34657172›Full record

ArticleCancer immunology, immunotherapy : CII2022

Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer.

Jun-Nan Guo, Du Chen, Shen-Hui Deng, Jia-Rong Huang, Jin-Xuan Song, Xiang-Yu Li, Bin-Bin Cui, Yan-Long Liu

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. The effect of combined head and tail approach during laparoscopic D3 lymph node dissection on pain severity and complications in patients with right colon cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jun-Nan Guo *Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, 150086, People's Republic of China.
Du Chen *The First Department of Oncological Surgery, The First People's Hospital of Xiangtan City, Xiangtan, 411100, People's Republic of China.
Shen-Hui DengDepartment of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150086, People's Republic of China.
Jia-Rong HuangDepartment of Clinical Medicine, North Sichuan Medical College, Nanchong, 637000, People's Republic of China.
Jin-Xuan SongDepartment of Clinical Medicine, North Sichuan Medical College, Nanchong, 637000, People's Republic of China.
Xiang-Yu LiDepartment of Clinical Medicine, North Sichuan Medical College, Nanchong, 637000, People's Republic of China.
Bin-Bin CuiDepartment of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, 150086, People's Republic of China. cbbhrb@163.com.
Yan-Long LiuDepartment of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, 150086, People's Republic of China. 2355@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-5254-3897
Harbin Medical University · CNNorth Sichuan Medical University · CNXiangshan County First People's Hospital · CN

Funding

Harbin Medical University Cancer Hospital Preeminence Youth Fund JCQN2019-04Medical Wisdom Research Fund by the Heilongjiang Sunshine Health Foundation H21L0802Nn10 Program of Harbin Medical University Cancer Hospital Nn102017-02Post-doctoral Scientific Research Developmental Fund of Heilongjiangn LBH-Q18085
6 · The paper itself

Abstract

backgroundThe left-sided and right-sided colon cancer (LCCs and RCCs, respectively) have unique molecular features and clinical heterogeneity. This study aimed to identify the characteristics of immune cell infiltration (ICI) subtypes for evaluating prognosis and therapeutic benefits.

methodsThe independent gene datasets, corresponding somatic mutation and clinical information were collected from The Cancer Genome Atlas and Gene Expression Omnibus. The ICI contents were evaluated by "ESTIMATE" and "CIBERSORT." We performed two computational algorithms to identify the ICI landscape related to prognosis and found the unique infiltration characteristics. Next, principal component analysis was conducted to construct ICI score based on three ICI patterns. We analyzed the correlation between ICI score and tumor mutation burden (TMB), and stratified patients into prognostic-related high- and low- ICI score groups (HSG and LSG, respectively). The role of ICI scores in the prediction of therapeutic benefits was investigated by "pRRophetic" and verified by Immunophenoscores (IPS) (TCIA database) and an independent immunotherapy cohort (IMvigor210). The key genes were preliminary screened by weighted gene co-expression network analysis based on ICI scores. And they were further identified at various levels, including single cell, protein and immunotherapy response. The predictive ability of ICI score for prognosis was also verified in IMvigor210 cohort.

resultsThe ICI features with a better prognosis were marked by high plasma cells, dendritic cells and mast cells, low memory CD4

conclusionThe identification of ICI subtypes and ICI scores will help gain insights into the heterogeneity in LCC and RCC, and identify patients probably benefiting from treatments. ICI scores and the key genes could serve as an effective biomarker to predict prognosis and the sensitivity of immunotherapy.

Indexed as

Colonic NeoplasmsImmunotherapyBiomarkers, TumorHumansPrognosisTetraspaninsBiomarkers, TumorTetraspaninsTSPAN1 protein, humanColon cancerImmune cell infiltration (ICI)Left-sidedPrognosisRight-sidedTherapeutic sensitivity

Identifiers

PMID34657172
PMCPMC9122887
OpenAlexW3205716412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.